Your browser doesn't support javascript.
Strategies for using antigen rapid diagnostic tests to reduce transmission of SARS-CoV-2 in low- and middle-income countries: a mathematical modelling study applied to Zambia.
Han, Alvin X; Girdwood, Sarah; Khan, Shaukat; Sacks, Jilian A; Toporowski, Amy; Huq, Naushin; Hannay, Emma; Russell, Colin A; Nichols, Brooke E.
  • Han AX; Department of Medical Microbiology & Infection Prevention, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
  • Girdwood S; Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Khan S; Clinton Health Access Initiative, Boston, MA, USA.
  • Sacks JA; Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland.
  • Toporowski A; Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland.
  • Huq N; Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland.
  • Hannay E; Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland.
  • Russell CA; Department of Medical Microbiology & Infection Prevention, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
  • Nichols BE; Department of Global Health, School of Public Health, Boston University, Boston, MA, USA.
Clin Infect Dis ; 2022 Oct 08.
Article in English | MEDLINE | ID: covidwho-2262043
ABSTRACT

BACKGROUND:

Increasing the availability of antigen rapid diagnostic tests (Ag-RDTs) in low- and middle-income countries (LMICs) is key to alleviating global SARS-CoV-2 testing inequity (median testing rate in December 2021-March 2022 when the Omicron variant was spreading in multiple countries; high-income countries = 600 tests/100,000 people/day; LMICs = 14 tests/100,000 people/day). However, target testing levels and effectiveness of asymptomatic community screening to impact SARS-CoV-2 transmission in LMICs are unclear.

METHODS:

We used PATAT, an LMIC-focused agent-based model to simulate COVID-19 epidemics, varying the amount of Ag-RDTs available for symptomatic testing at healthcare facilities and asymptomatic community testing in different social settings. We assumed that testing was a function of access to healthcare facilities and availability of Ag-RDTs. We explicitly modelled symptomatic testing demand from non-SARS-CoV-2 infected individuals and measured impact based on the number of infections averted due to test-and-isolate.

RESULTS:

Testing symptomatic individuals yields greater benefits than any asymptomatic community testing strategy until most symptomatic individuals who sought testing have been tested. Meeting symptomatic testing demand likely requires at least 200-400 tests/100,000 people/day on average as symptomatic testing demand is highly influenced by non-SARS-CoV-2 infected individuals. After symptomatic testing demand is satisfied, excess tests to proactively screen for asymptomatic infections among household members yields the largest additional infections averted.

CONCLUSIONS:

Testing strategies aimed at reducing transmission should prioritize symptomatic testing and incentivizing test-positive individuals to adhere to isolation to maximize effectiveness.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Diagnostic study Topics: Variants Language: English Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Cid

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Diagnostic study Topics: Variants Language: English Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Cid